• In June 2026, Dexcom announced that the FDA had cleared its Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children aged two and older who do not use insulin, extending its earlier adult-only OTC authorization.
• This move positions Dexcom to reach pediatric patients with prediabetes or non-insulin-treated diabetes, potentially broadening CGM use for lifestyle and medication management at home.
• We’ll now examine how opening over-the-counter pediatric access to Stelo could influence Dexcom’s long-term growth, risk profile, and investment narrative.

We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

DexCom Investment Narrative Recap

To own DexCom, you need to believe continuous glucose monitoring can keep expanding beyond intensive insulin users into far larger type 2 and prediabetes populations. The new pediatric OTC clearance for Stelo strengthens that story at the margin by widening DexCom’s consumer-facing footprint, but it does not directly change the key near term swing factors: how quickly type 2 coverage converts into paying users and how much pressure CMS bidding and competitors put on pricing and margins.

Among recent developments, the CONNECT trial showing meaningful A1C reductions in type 2 patients not on insulin matters most here, because it supports broader CGM use in the same non insulin, often prediabetic, population that Stelo now targets OTC. Together, the data and the new pediatric label give DexCom more clinical and regulatory support as it tries to convert covered lives into active users, which remains a central catalyst for the stock.

Yet against this backdrop, investors should still watch how potential CMS bidding and intensifying competition could affect pricing power and long term profitability...

DexCom's narrative projects $6.7 billion revenue and $1.4 billion earnings by 2029.

Uncover how DexCom's forecasts yield a $83.42 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already assuming only about US$6.4 billion of revenue and US$1.4 billion of earnings by 2029, so if you worry that even expanded OTC Stelo access could still leave many covered patients unconverted and growth capped around high single digits, their more cautious view on adoption and margins may resonate with you.

Explore 6 other fair value estimates on DexCom - why the stock might be worth just $83.42!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your DexCom research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free DexCom research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DexCom's overall financial health at a glance.

No Opportunity In DexCom?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.